Sanofi Releases Stock Exchange Announcements and Disclosures for India Operations

Sanofi, the global pharmaceutical giant, has made public a series of stock exchange announcements and disclosures specifically concerning its operations in India. These documents, spanning from 2022 to 2026, provide investors with essential regulatory and corporate governance information relevant to its Indian market presence.

The disclosures cover a range of corporate events and compliance matters. These include intimations regarding the closure of trading windows, a standard procedure for listed companies around financial reporting periods and dividend announcements. Furthermore, the company has disclosed changes in senior management personnel, including resignations and appointments, which are critical for understanding the company's leadership structure in India.

Specific financial and governance-related information is also detailed. This includes communications regarding tax deductions at source for the year 2025, and tax information related to dividend distributions for 2023. For 2024, Sanofi Consumer Healthcare India Limited has issued clarifications and announcements regarding the appointment of independent directors, providing transparency on its board composition.

In addition to these formal disclosures, Sanofi has also made recordings of investor and analyst calls available for 2023 and 2022. These calls offer deeper insights into the company's financial performance, strategic direction, and outlook for the Indian market, allowing stakeholders to engage directly with the company's management. The information is presented in line with stock exchange requirements and is accessible via Sanofi's investor relations website, primarily through PDF documents and supplementary video recordings.